Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page
- Check4 days agoChange Detected- Added a new Locations section listing Michigan, Nebraska, New Jersey, New York, and Wisconsin. Removed the separate Michigan, Nebraska, New Jersey, New York, and Wisconsin location blocks.SummaryDifference0.7%
- Check18 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; this appears to be a minor backend or formatting change with no edits to study details, eligibility, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check32 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1 on the page.SummaryDifference0.1%
- Check40 days agoChange DetectedThe funding status warning banner was removed from the page, removing the notice about potential information delays due to government funding. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check54 days agoChange DetectedStudy Details page appears unchanged; no additions or deletions detected.SummaryDifference0.5%
- Check83 days agoChange DetectedKey updates: version bump to v3.2.0 and the new government-operating-status notice; the previous v3.1.0 reference was removed. This indicates an update to status information and release version.”} }``` If the tool requires plain JSON, remove the trailing period. If needed: End. } }}SummaryDifference3%
Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.